About Liprin-alpha-3
Liprin-alpha-3 (PPFIA3) is a protein
from Homo sapiens identified by UniProt accession
O75145, 1194 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Liprin-alpha-3 |
|---|
| UniProt accession | O75145 |
|---|
| Gene | PPFIA3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1194 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.36
- Neurodevelopmental delay · score 0.33
- body mass index · score 0.21
- genetic disorder · score 0.19
- Neurodevelopmental disorder · score 0.19
- cutaneous melanoma · score 0.17
- systolic blood pressure · score 0.17
- squamous cell lung carcinoma · score 0.16
- body height · score 0.12
- head and neck squamous cell carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75145-F1 | alphafold | PREDICTED | 68.89 | — |
Amino-acid sequence (1194 residues)
MMCEVMPTIS EDGRRGSALG PDEAGGELER LMVTMLTERE RLLETLREAQ DGLATAQLRL RELGHEKDSL QRQLSIALPQ EFAALTKELN LCREQLLERE EEIAELKAER NNTRLLLEHL ECLVSRHERS LRMTVVKRQA QSPGGVSSEV EVLKALKSLF EHHKALDEKV RERLRMALER VAVLEEELEL SNQETLNLRE QLSRRRSGLE EPGKDGDGQT LANGLGPGGD SNRRTAELEE ALERQRAEVC QLRERLAVLC RQMSQLEEEL GTAHRELGKA EEANSKLQRD LKEALAQRED MEERITTLEK RYLSAQREAT SLHDANDKLE NELASKESLY RQSEEKSRQL AEWLDDAKQK LQQTLQKAET LPEIEAQLAQ RVAALNKAEE RHGNFEERLR QLEAQLEEKN QELQRARQRE KMNDDHNKRL SETVDKLLSE SNERLQLHLK ERMGALEEKN SLSEEIANMK KLQDELLLNK EQLLAEMERM QMEIDQLRGR PPSSYSRSLP GSALELRYSQ APTLPSGAHL DPYVAGSGRA GKRGRWSGVK EEPSKDWERS APAGSIPPPF PGELDGSDEE EAEGMFGAEL LSPSGQADVQ TLAIMLQEQL EAINKEIKLI QEEKETTEQR AEELESRVSS SGLDSLGRYR SSCSLPPSLT TSTLASPSPP SSGHSTPRLA PPSPAREGTD KANHVPKEEA GAPRGEGPAI PGDTPPPTPR SARLERMTQA LALQAGSLED GGPPRGSEGT PDSLHKAPKK KSIKSSIGRL FGKKEKGRMG PPGRDSSSLA GTPSDETLAT DPLGLAKLTG PGDKDRRNKR KHELLEEACR QGLPFAAWDG PTVVSWLELW VGMPAWYVAA CRANVKSGAI MANLSDTEIQ REIGISNPLH RLKLRLAIQE MVSLTSPSAP ASSRTSTGNV WMTHEEMESL TATTKPETKE ISWEQILAYG DMNHEWVGND WLPSLGLPQY RSYFMESLVD ARMLDHLNKK ELRGQLKMVD SFHRVSLHYG IMCLKRLNYD RKDLERRREE SQTQIRDVMV WSNERVMGWV SGLGLKEFAT NLTESGVHGA LLALDETFDY SDLALLLQIP TQNAQARQLL EKEFSNLISL GTDRRLDEDS AKSFSRSPSW RKMFREKDLR GVTPDSAEML PPNFRSAAAG ALGSPGLPLR KLQPEGQTSG SSRADGVSVR TYSC
Explore Liprin-alpha-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets